Health and wellness influencers are hawking unapproved treatments on the gray market. The future of the F.D.A.—and the health ...

OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...

MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...

On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.

Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is safe and ...

Learn why rapid weight loss may trigger hair loss with Ozempic and discover ways to minimize shedding and regrow your hair.

Optimal management of Parkinson's disease requires timely recognition of progression, careful patient selection, and a ...

Federal health regulators have formally warned ImmunityBio Inc. for making misleading promotional claims about Anktiva, the ...